Modi Naturals Q2 FY27: PAT up just 9% YoY as branded/bulk margins offset ethanol surge

Consolidated revenue rose to ₹204.90 Cr, up 39.4% YoY and 31.7% QoQ, almost entirely on the Ethanol segment (₹117.46 Cr, +37.9% YoY, +54.1% QoQ) as the doubled ethanol capacity continues to ramp. But consolidated PAT of ₹11.02 Cr grew only 9.4% YoY and fell 11.8% QoQ from ₹12.50 Cr in Q1 FY27 (EPS ₹8.33 vs ₹7.58 YoY and ₹9.44 QoQ), so profit growth trailed topline growth by a wide margin. NPM compressed to 5.37% from 6.82% (YoY) and 8.05% (QoQ); OPM fell to 9.26% from 10.44% (YoY) and 14.25% (QoQ). The margin squeeze did not come from Ethanol, which held EBITDA margin at 15.78% this quarter (18.15% for H1) — at or above management's own 12-15% long-term guide for the division. It came from the other two segments: Branded EBITDA margin collapsed to 2.12% (from 9.38% in Q1 and 7.16% a year ago), and Bulk swung to a segment EBITDA loss of ₹0.51 Cr (from +₹1.25 Cr in Q1, +₹0.40 Cr a year ago). The standalone entity, which carries only Branded and Bulk (Ethanol sits entirely in Modi Biotech, consolidated-only), was effectively breakeven at ₹0.02 Cr PAT on ₹0.01 Cr PBT, against ₹2.63 Cr a year ago — a stark reminder that the core consumer oils/food business is under real pressure even as ethanol drives the consolidated headline. No press release accompanied this filing, so this reading is drawn from the result statement and the prior concall only. Against management's FY27 guidance (revenue ₹925-965 Cr, EBITDA ₹100-105 Cr, PAT ₹66-70 Cr, confirmed post the May 2026 concall), H1 FY27 consolidated revenue of ₹361.95 Cr is ~38% of the full-year range and PAT of ₹23.53 Cr is ~35% — close to the company's own historical H1 skew (H1 FY26 was 42% of FY26 revenue and 41% of FY26 PAT), so the pace looks broadly on track rather than off course, though H2 will need the margin trend to stabilise rather than repeat this quarter's compression. No analyst consensus estimates for this specific quarter turned up in search (small-cap, thin broker coverage), so street comparison is unknown. The only hard corporate development on record this quarter is the ₹140 Cr ethanol order win for Modi Biotech (17-Aug-2026), consistent with the ethanol-led revenue surge; management's May-2026 bullish, confident tone on ethanol is so far borne out, but its branded-division ambitions (medium-term ₹500 Cr target, H1 branded revenue ₹87.44 Cr) show no comparable momentum this quarter.